HSPPR temporarily limits intakes after disease found in multiple dogs
The Humane Society of the Pikes Peak Region (HSPPR) is temporarily limiting dog intakes after discovering multiple cases of ...
Managed Healthcare Executive2d
FDA Accepts NDA for Gilead's New HIV Prevention Shot
Lenacapavir is a twice-yearly injectable medication designed to be used as pre-exposure prophylaxis (PrEP). The FDA is giving ...
Targeted Oncology6d
Defibrotide Does Not to Prevent Sinusoidal Obstruction Syndrome in High-Risk Pediatric HSCT
Defibrotide prophylaxis after HSCT did not reduce sinusoidal obstructive syndrome incidence in high-risk pediatric patients, per retrospective study at 2025 Tandem Meeting.
Southern Eye on MSN4d
Jobs lost and treatment stopped as USAid freeze hits HIV care in Zim
Gumisayi Bonzo, a director at Trans Smart Trust, an organisation offering HIV and Aids services to transgender and intersex ...
News Day3d
‘Disruptive, unfair and cruel’: Jobs lost and treatment stopped as USAid freeze hits HIV care in Zim
Gumisayi Bonzo, a director at Trans Smart Trust, an organisation offering HIV and Aids services to transgender and intersex ...
Sun Star1d
Animal bite cases in Lapu rise by 54% in January
ANIMAL bite cases involving both stray and pet animals in Lapu-Lapu City have increased by 54.8 percent, with the Animal Bite ...
pharmaphorum1d
FDA sets June date for Gilead's twice-yearly HIV PrEP
Analysts at RBC Capital Markets have predicted twice-yearly lenacapavir could become a $2 billion product, and become a key ...
dvm3606d
Managing canine oral tumors
Several important steps should be taken and/or considered after the identification of an oral cavity lesion: Perform a ...
unaids2d
How the shift in US funding is threatening both the lives of people affected by HIV and the community groups supporting them
In a joint survey by Aidsfonds, GNP+ and the Robert Carr Fund 22% of organizations reported increased experiences of discrimination, including reports of discrimination within healthcare settings, ...
PharmiWeb1d
U.S. FDA Accepts Gilead’s New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions for lenacapavir—the company’s twice-yearly ...
The Citizen3d
Gauteng sees drop in HIV and STI infections
Human immunodeficiency virus (HIV) and sexually transmitted infections (STI) infections dropped in Gauteng between 2020 and 2024. The Gauteng Department of Health (GDoH) on Sunday ...
dermatologyadvisor10h
Hidradenitis Suppurativa Treatment Guidelines Issued for Special Populations
A total of 118 recommendations based on expert consensus were published regarding the treatment of hidradenitis suppurativa ...